Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule

European Journal of Pharmaceutical Sciences

Volumn 4, Issue 1, 1996, Pages 1-22

  Christiaans, J A M ^a,b   Timmerman, H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID METHYL 2 PHENYLTHIOETHYL ESTER; ACETYLSALICYLIC ACID; AMLODIPINE; AMOSULALOL; ANTIALLERGIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; AROTINOLOL; BENORILATE; BEVANTOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; CELIPROLOL; DICOUMAROL; DIHYDROPYRIDINE DERIVATIVE; DILEVALOL; DIURETIC AGENT; EPANOLOL; ETACRYNIC ACID; LABETALOL; METOPROLOL; NITRITE; PHOSPHODIESTERASE INHIBITOR; PREDNISOLONE 21 PHOSPHATE; PREDNISOLONE HEMISUCCINATE; PRODRUG; UNINDEXED DRUG; VASODILATOR AGENT;

DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYBRID; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEREOISOMERISM;

EID: 0030026323     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/0928-0987(95)00029-1     Document Type: Review

References (64)

1. Alker, D., Campbell, S.F., Cross, P.E., Burges, R.A., Carter, A.J. and Gardiner, D.G. (1990) Long-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[N-substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine calcium antagonists. J. Med. Chem. 33, 1805-1811.
2. Allan, G., Cambridge, D., Hardy, G.W., Follenfant, M.J., Ford, A. and Oliver, P.L. (1986) BW A575C, a novel antihypertensive agent with angiotensin converting enzyme inhibition and beta-blocking properties. J. Hypertension 4, S131-S133.
3. Amschler, H., Eistetter, K., Eltze, M., Flockerzi, D., Klemm, K., Kolassa, N., Sanders, K., Schudt, C. and Ruediger, W.U. (1987) Substituted 1,4-dihydro-3-pyridinecarboxylic acid derivatives, their preparation, pharmaceuticals containing them, and their use as cardiovascular agents. Chem. Abstr. 106, 176183h.
4. Archibald, J.L., Bradley, G., Opalko, A., Ward, T.J., White, J.C., Ennis, C. and Shepperson, N.B. (1990) Design of an antithrombotic-antihypertensive agent (Wy 27569). Synthesis and evaluation of a series of 2-heteroaryl-substituted dihydropyridines. J. Med. Chem. 33, 646-652.
5. Ariëns, E.J. (1971) A general introduction to the field of drug design. In: E.J. Ariens (editor), Drug Design, 1. Academic Press, New York.
6. Ariëns, E.J. (1988) Stereochemical implications of hybrid and pseudo-hybrid drugs (Part III). Med. Res. Rev. 8, 309-320.
7. Arrowsmith, J.E., Campbell, S.F., Cross, P.E., Stubbs, J.K., Burges, R.A., Gardiner, D.G. and Blackburn, K.J. (1986) Long acting dihydropyridine Ca-antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J. Med. Chem. 29, 1696-1702.
8. Baldwin, J.J., Hirschmann, R., Engelhardt, E.L., Ponticello, G.S., Sweet, C.S. and Scriabine, A. (1981) Approaches to vasodilating/β-adrenergic blocking agents: examples of the dihydrolutidine type. J. Med. Chem. 24, 628-631.
9. 1-adrenoceptors. Eur. J. Pharmacol.-Mol. Pharmacol. 172, 131-145.
10. Brittain, R.T. and Levy, G.P. (1976) A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor blocking drug. Br. J. Clin. Pharmacol 3, supplement.
11. Brittain, R.T., Drew, G.M. and Levy, G.P. (1982) The alpha- and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br. J. Pharmacol. 77, 105-114.
12. Cecchetti, V., Schiaffella, F., Tabarrini, O., Zhou, W., Fravolini, A., Goi, A., Bruni, G. and Segre, G. (1991) Symbiotic approach to drug design: N-[(4-chloro-3-sulfamoylbenzamido)ethyl] propanolamine derivatives as β-adrenergic blocking agents with diuretic activity. Eur. J. Med. Chem. 26, 381-386.
13. Cecchetti, V., Fravolini, A., Schiaffella, F., Tabarrini, O., Bruni, G. and Segre, G. (1993) o-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as β-blocking/diuretic agents. J. Med. Chem. 36, 157-161.
14. Christiaans, J.A.M., Windhorst, A.D., Groenenberg, P.M., Van der Goot, H. and Timmerman H. (1993a) Synthesis and in vitro pharmacology of new 1,4-dihydropyridines. 1. 2-(ω)-Aminoalkylthiomethyl)-1,4-dihydropyridines as potent calcium channel blockers. Eur. J. Med. Chem. 28, 859-867.
15. Christiaans, J.A.M., Van der Goot, H., Timmerman H. (1993b) Synthesis and in vitro pharmacology of a series of new 1,4-dihydropyridines. 2. Diethyl 4-[2-(ω-aminoalkoxy)phenyl] - 2,6 - dimethyl - 1,4 - dihydropyridine - 3,5-dicarboxylates and their corresponding isothioureas as tools for determining structure-activity relationships. Eur. J. Med. Chem. 28, 935-941.
16. 2-agonistic properties. Eur. J. Med. Chem. 29, 579-593.
17. Cooper, K., Fray, M.J., Parry, M.J., Richardson. K. and Steele, J. (1992) 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives. J. Med. Chem. 35, 3115-3129.
18. 2 antagonism and thromboxane A1 synthase inhibition. J. Med. Chem. 36, 2964-2972.
19. Eltze, M., Boer, R., Sanders, K.H., Boss, H., Ulrich, W.-R. and Flockerzi, D. (1990) Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists. Chirality 2, 233-240.
20. Ennis, C., Granger. S.E., Middlefell, V.C., Philpot, M.E. and Shepperson, N.B. (1989) Pharmacologic effects of Wy 27569: a combined calcium channel blocker and thromboxane synthetase inhibitor. J. Cardiovasc. Pharmacol. 13, 511-519.
21. Erhardt, P.W. (1987) In search of the digitalis replacement. J. Med. Chem. 30, 231-237.
22. 2-receptor stimulation in congestive heart failure. Hemodynamic effects of BU-E-76, BU-E-75 and arpromidine (BU-E-50) in comparison to impromidine. Agents Actions Suppl. 33, 257-269.
23. Fernandez-Gallardo, S. Pilar Ortega, M., Priego, J.G., Fau de Casa-Juana, M., Sunkel, C. and Sanchez Crespo, M. (1990) Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies. J. Pharmacol. Exp. Ther. 255, 34-39.
24. 2-agonistic and PDE III inhibitory activity. Arch. Pharm. (Weinheim) 324, 669.
25. 2-agonistic and PDE III inhibitory activity. Poster presentation 21st Annu. Meet. European Histamine Research Society, 13-17 May, Malaga, Spain.
26. Görlitzer, K. and Düwel, W. (1992) 1,4-Dihydropyridine mit Etacrynsäure-Partialstruktur. Arch. Pharm. (Weinheim) 325, 361-364.
27. 3H]5-methyl-urapidil. Eur. J. Pharmacol.-Mol. Pharmacol. 172, 329-337.
28. Josiyn, A.F., Luchowski, E. and Triggle, D.J. (1988) Dimeric 1,4-dihydropyridines as calcium channel antagonists. J. Med. Chem. 31, 1489-1492.
29. Kajino, M., Wada, Y., Nagai, Y., Nagaoka, A. and Meguro, K. (1989) Synthesis and biological activities of optical isomers of 2-(4-diphenylmethyl-1-piperazinyl)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate (manidipine) dihydrochloride. Chem. Pharm. Bull. 37, 2225-2228.
30. Kau, ST., Howe, B.B., Li, H.-Y., Smith, L.H., Keddie, J.R., Barlow, J.J., Giles, R.E. and Goldberg, M.E. (1987) ICI 147,798: a novel diuretic agent with beta adrenoceptor blocking activity. J. Pharmacol. Exp. Ther. 242, 818-826.
31. Kawamura, J., Gotoh, F., Fukuuchi, Y., Amano, T., Tanaka, K., Uematsu, D., Suzuki, N., Kobari, M, and Obara, K. (1988) Effects of the new calcium antagonist 2-nitratopropyl-3-nitratopropyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4- dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats. Arzneim.-Forsch./Drug Res. 38, 221-224.
32. Kawashima, Y., Ogawa, T., Kato, M., Nakazato, A., Tsuchida, K., Hatayama, K., Hirono, S. and Moriguchi, I. (1993) Structure-activity study of antihypertensive 1,4-dihydropyridine derivatives having nitrooxyalkyl moieties at the 3 and 5 positions. Chem. Pharm. Bull. 41, 1060-1065.
33. 1-adrenoceptor antagonist. Bioorg. Med. Chem. Lett. 3, 561-564.
34. Lis, R., Morgan, T.K., Jr., Marisca, A.J., Gomez, R.P., Lind, J.M., Davey, D.D., Phillips, G.B. and Sullivan, M.E. (1990) Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhytmic activity. J. Med. Chem. 33, 2883-2891.
35. Marciniak, G., Delgado, A., Leclerc, G., Velly, J., Decker, N. and Schwartz, J. (1989) New 1,4-dihydropyridine derivatives combining calcium antagonism and a-adrenolytic properties. J. Med. Chem. 32, 1402-1407.
36. Meguro, K., Aizawa, M., Sohda, T., Kawamatsu, Y. and Nagaoka, A. (1985) New 1,4-dihydropyridine derivatives with potent and long-lasting antihypertensive effect. Chem. Pharm. Bull. 33, 3787-3797.
37. Morgan, T.K., Jr., Lis, R., Lumma, W.C., Jr., Nickisch, K., Wohl, R.A., Phillips, G.B., Gomez, R.P., Lampe, J.W., Di Meo, S., Marisca, A.J. and Forest, J. (1990a) Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides - new selective class III agents. J. Med. Chem. 33, 1091-1097.
38. Morgan, T.K. Jr., Lis, R., Lumma, W.C. Jr., Wohl, R.A., Nickisch, K., Phillips, G.B., Lind, J.M., Lampe, J.W., Di Meo, S., Reiser, J., Argentieri, T., Sullivan, M.E. and Cantor. E. (1990b) Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phenoxy]-ethyl]amino]propoxy]phenyl] methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities. J. Med. Chem. 33, 1087-1090.
39. Ogawa, T., Nakazato, A., Tsuchida, K. and Hatayama, K. (1993a) Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5-positions. Chem. Pharm. Bull. 41, 1049-1054.
40. Ogawa, T., Matsumoto. K., Yokoo, C., Hatayama, K. and Kitamura, K. (1993b) Synthesis and configurational assignment of methyl 3-nitrooxypropyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. J. Chem. Soc. Perkin. Trans I, 525-528.
41. Ohira, A., Wada, Y., Fujii, M., Nakamura, M., Kasuya, Y., Hamada, Y. and Shigenobu, K. (1985) Effects of nipradilol (K-351) on alpha-adrenoceptor mediated responses in various isolated tissues. Arch. Int. Pharmacodyn. 278, 61-71.
42. Okada, Y., Yanagisawa, T. and Taira, N. (1991) An analysis of the nitrate-like and K channel opening actions of KRN2391 in canine coronary arterial smooth muscle. Br. J. Pharmacol. 104, 829-838.
43. Phillips, G.B., Morgan, T.K., Jr., Lumma, W.C., Jr., Gomez, R.P., Lind, J.M., Lis, R., Argentieri, T. and Sullivan, M.E. (1992) Synthesis, cardiac electrophysiology, and β-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents. J. Med. Chem. 35, 743-750.
44. Pilar Ortega, M., Del Carmen Garcia, M., Gijon. M. A., Fau de Casa-Juana, M., Priego, J.G., Sanchez Crespo, M. and Sunkel, C. (1990) 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. J. Pharmacol. Exp. Ther. 255, 28-33.
45. Rahn, K.H. (1990) Principles in the combination of antihypertensive drugs. In: D. Ganten and P.J. Mulrow (editors). Handbook of Experimental Pharmacology: Pharmacology of Antihypertensive Therapeutics. 93. Springer, Berlin, pp. 677-685.
46. Schickaneder, H., Mörsdorf, P., Buschauer, A., Schunack, W., Engler, H.,Vergin, H. and Ahrens, K. (1988) 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel. DE 3621104.
47. Shaffer, J.E., Grizzle, M.K., Anderson, D.K. and Wheeler, T.N. (1993) The inotropic and beta blocking effects of a chimeric molecule that putatively inhibits both type III phosphodiesterase and beta adrenoceptors in anesthetized dogs. J. Pharmacol. Exp. Ther. 265, 1105-1112.
48. Slater, R.A., Howson, W., Swayne, G.T.G., Taylor, E.M. and Reavill, D.R. (1988) Design and synthesis of a series of combined vasodilator/β-adrenoceptor antagonists based on 6-arylpyridazinones. J. Med. Chem. 31, 345-351.
49. Sponer, G., Bartsch, W. and Hooper, R.G. (1990) Drugs acting on multiple receptors: β-blockers with additional properties. In: D. Ganten and P.J. Mulrow, P.J. (editors). Handbook of Experimental Pharmacology: Pharmacology of Antihypertensive Therapeutics, 93. Springer, Berlin, pp. 131-226
50. 1- adrenoceptor antagonist. J. Cardiovasc. Pharmacol. 11, 387-395.
51. Sterk, G. J., Van der Werf, J.F., Timmerman, H. and Bron, J. (1991) Novel 1,4-dihydropyridines. PCT/EP91/01442.
52. Sunkel, C.E., Fau de Casa-Juana, M., Cillero, F.J., Priego, J.G. and Pilar Ortega, M. (1988) Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. J. Med. Chem. 31, 1886-1890.
53. Sunkel, C.E., Fau de Casa-Juana, M., Santos, L., Gómez, M.M., Villarroya, M., González-Morales, M.A., Priego, J.G. and Pilar Ortega, M. (1990) 4-Alkyl-1,4-dihydropyridine derivatives as specific PAF-acether antagonists. J. Med. Chem. 33, 3205-3210.
54. Swayne, G.T.G., Owen, D.A.A., Taylor, E.M., Eden, R.J., Slater, R.A. and Howson, W. (1987) SK&F 95018, a vasodilator/β-adrenoceptor antagonist. Arch. Int. Pharmacodyn. 289, 251-266.
55. Taira, N. (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am. J. Cardiol. 63, 18J-24J.
56. Taylor, E.M., Eden, R.J., Fielden, R. and Owen, D.A.A. (1981) Studies on the autonomic nervous system with SK&F92657, a new antihypertensive agent causing direct arterial vasodilatation and β-adrenoceptor blockade. J. Cardiovasc. Pharmacol. 3, 355-368.
57. Tsuchida, K., Yamazaki, R., Kaneko, K. and Aihara, H. (1987) Effects of the new calcium antagonist 2-nitratopropyl - 3 - nitratopropyl - 2,6 -dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in dogs. Arzneim.-Forsch./Drug Res. 37, 1239-1243.
58. Uchida, Y., Nakamura, M., Shimizu, S., Shirasawa, Y. and Fujii, M. (1983) Vasoactive and β-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch. Int. Pharmacodyn. 262, 132-149.
59. Van der Goot, H., Bast, A. and Timmerman, H. (1991) In: B. Uvnäs, B. (editor) Handbook of Experimental Pharmacology: Histamine and Histamine Antagonists, 97. Springer, Berlin, pp. 573-748.
60. Van Zwieten, P.A. (1988) Basic pharmacology of alpha-adrenoceptor antagonists and hybrid drugs. J. Hypertension 6(suppl. 2), S3-S11.
61. Van Zwieten, P.A. and Prichard, B.N.C. (1989) Urapidil: an antihypertensive drug with multifactorial action. Ann. Fr. Anesth. Réanim. 8, 4-7.
62. Van Zwieten, P.A. (1990a) α-Adrenoceptor antagonists. In: D. Ganten and P.J. Mulrow (editors). Handbook of Experimental Pharmacology: Pharmacology of Antihypertensive Therapeutics, 93. Springer, Berlin, pp. 105-129.
63. Van Zwieten, P.A. (1990b) Hybrid or multifactorial drugs in antihypertensive treatment. J. Hypertension 8, 687-696.
64. Willard, A.K., Smith. R.L. and Cragoe, E. J., Jr. (1981) Potential diuretic-β-adrenergic blocking agents: synthesis of 3-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,4-dioxino[2,3-g] quinolines. J. Org. Chem. 46, 3846-3852.